Modelling optimal vaccination strategy for SARS-CoV-2 in the UK

Author:

Moore SamORCID,Hill Edward M.ORCID,Dyson LouiseORCID,Tildesley Michael J.ORCID,Keeling Matt J.ORCID

Abstract

The COVID-19 outbreak has highlighted our vulnerability to novel infections. Faced with this threat and no effective treatment, in line with many other countries, the UK adopted enforced social distancing (lockdown) to reduce transmission—successfully reducing the reproductive number R below one. However, given the large pool of susceptible individuals that remain, complete relaxation of controls is likely to generate a substantial further outbreak. Vaccination remains the only foreseeable means of both containing the infection and returning to normal interactions and behaviour. Here, we consider the optimal targeting of vaccination within the UK, with the aim of minimising future deaths or quality adjusted life year (QALY) losses. We show that, for a range of assumptions on the action and efficacy of the vaccine, targeting older age groups first is optimal and may be sufficient to stem the epidemic if the vaccine prevents transmission as well as disease.

Funder

National Institute for Health Research

Engineering and Physical Sciences Research Council

Medical Research Council

Publisher

Public Library of Science (PLoS)

Subject

Computational Theory and Mathematics,Cellular and Molecular Neuroscience,Genetics,Molecular Biology,Ecology,Modelling and Simulation,Ecology, Evolution, Behavior and Systematics

Reference56 articles.

1. Control for Disease Prevention EC. Covid-19 situation update worldwide, as of 16 august 2020. https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases (accessed August, 2020).

2. NHS UK. Check if you or your child has coronavirus symptoms (2020). https://www.nhs.uk/conditions/coronavirus-covid-19/symptoms/. [Online] (Accessed: 11 December 2020).

3. News B. Coronavirus vaccine: Uk government signs deals for 90 million doses. https://www.bbc.co.uk/news/health-53772650 (accessed August, 2020).

4. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored covid-19 vaccine candidate chadox1 ncov-19;SP Graham;npj Vaccines,2020

5. Safety and immunogenicity of the chadox1 ncov-19 vaccine against sars-cov-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial;PM Folegatti;The Lancet,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3